Johnson & Johnson reaches $5.5 bn talc settlement to resolve ovarian‑cancer lawsuits
Johnson & Johnson announced a proposed settlement worth at least $5.5 billion to end tens of thousands of lawsuits alleging its talc‑based baby powder caused ovarian cancer. The deal would cover an estimated 76,000 pending claims and will take effect only if at least 95 % of eligible claimants agree to participate.
The settlement is voluntary and was negotiated outside of bankruptcy court. It does not bind unwilling participants and does not cover future lawsuits. J&J said a first payment of $3 billion is scheduled for next year, with the remaining balance to be paid by 2028. The company maintains its talc products are safe, asbestos‑free and not linked to cancer, and says the agreement allows it to focus on its core medical businesses.
If the participation threshold is met, the settlement is expected to resolve the claims within about 18‑24 months, providing faster compensation than the earlier bankruptcy‑based proposals that were rejected by courts.
Entities: Chris Seeger · Erik Haas · Johnson & Johnson · New Jersey · Ovarian cancer claimants · Talc litigation · US federal courts · United States federal courts · ovarian cancer · ovarian cancer victims · plaintiffs' law firms · talc‑based baby powder
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [● 6 SOURCES] The settlement is voluntary and negotiated outside bankruptcy court. (All articles note the deal is voluntary and not filed through a bankruptcy proceeding.)
- [● 6 SOURCES] Johnson & Johnson will make a first payment of $3 billion next year, with the remainder paid by 2028. (Three articles specify a $3 bn initial payment and further payments due by 2028.)
- [● 6 SOURCES] Johnson & Johnson agreed to pay at least $5.5 billion to settle talc‑related lawsuits. (One or more of the articles propose a $5.5 bn settlement.)
- [● 6 SOURCES] The settlement requires participation of at least 95 % of eligible claimants to proceed. (All articles note the 95 % threshold for the settlement to become effective.)
- [● 6 SOURCES] The settlement aims to resolve about 76,000 ovarian‑cancer claims. (All articles report the settlement would cover roughly 76,000 pending claims.)
- [● 6 SOURCES] Johnson & Johnson maintains its talc products are safe and asbestos‑free, denying a causal link to cancer. (All articles quote J&J’s stance that its talc is safe and does not cause cancer.)
- [● 6 SOURCES] Three prior attempts to resolve the litigation through bankruptcy were rejected by courts. (new)
- [● 2 SOURCES] The settlement covers only existing claims, not future lawsuits.
- [● 2 SOURCES] Johnson & Johnson maintains that its talc products are safe and asbestos‑free, denying any link to cancer. (Johnson & Johnson)
- [● 3 SOURCES] Johnson & Johnson previously attempted three bankruptcy filings to resolve the talc litigation, all of which were rejected by US courts. (Johnson & Johnson)
- [● 6 SOURCES] The settlement is expected to resolve claims within 18–24 months. (Three articles give an 18‑month or less‑than‑two‑year timeline for payouts.)
- [● 3 SOURCES] The settlement requires at least 95 % of eligible claimants to participate. (Johnson & Johnson)